Phase 3 study of soticlestat adjunctive therapy in Dravet syndrome

Phase 3, randomised, double-blind trial in Dravet syndrome comparing Soticlestat + standard of care with Placebo + standard of care (2 arms). Primary endpoints: Percent change from baseline in convulsive seizure frequency per 28 days during the full treatment period and Percent change from baseline in convulsive seizure frequency per 28 days during the maintenance period. Started Mar 2022; status: completed.